Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PRO CAR 201

Next Previous
Drug Profile

PRO CAR 201

Alternative Names: Anti-STEAP1 CAR T-cells - Promicell/Fred Hutchingson Cancer Research Center; Autologous STEAP 1 CAR T - PromiCell Therapeutics/Fred Hutchingson Cancer Research Center; PRO CAR-201A; PRO CAR-201B; STEAP 1 CAR T for Prostate Cancer - Fred Hutchingson Cancer Research Center/PromiCell Therapeutics

Latest Information Update: 03 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Fred Hutchinson Cancer Research Center
  • Developer Fred Hutchinson Cancer Research Center; PromiCell Therapeutics
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Prostate cancer
  • Preclinical Ewing's sarcoma

Most Recent Events

  • 26 Nov 2024 Phase-I clinical trials in Prostate cancer (Second-line therapy or greater, Adjuvant therapy, Hormone refractory, Late-stage disease, Metastatic disease) in USA (IV)
  • 31 Jan 2024 PromiCell Therapeutics intends to enrol patients in a phase I study in Ewing Sarcoma by second half of 2025 (PromiCell Therapeutics, January 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top